Bone Mass Loss Due to Estrogen Deficiency Is Compensated in Transgenic Mice Overexpressing Human Osteoblast Stimulating Factor-1

1997 ◽  
Vol 238 (2) ◽  
pp. 528-533 ◽  
Author(s):  
Haruchika Masuda ◽  
Atsushi Tsujimura ◽  
Makoto Yoshioka ◽  
Yuji Arai ◽  
Yoshinori Kuboki ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Bone Mass ◽  
Mass Loss ◽  
Estrogen Deficiency ◽  
Human Osteoblast ◽  
Bone Mass Loss ◽  
Stimulating Factor

Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency‐induced bone mass loss by modulating TRAF6‐mediated signaling

2018 ◽  
Vol 33 (2) ◽  
pp. 2574-2586 ◽  
Author(s):  
Bin Hu ◽  
Xuewu Sun ◽  
Yute Yang ◽  
Zhimin Ying ◽  
Jiahong Meng ◽  
...  
Keyword(s):  
Bone Mass ◽  
Mass Loss ◽  
Estrogen Deficiency ◽  
Bone Mass Loss

Bone mass increase specific to the female in a line of transgenic mice overexpressing human osteoblast stimulating factor-1

2004 ◽  
Vol 22 (3) ◽  
pp. 278-282 ◽  
Author(s):  
Tamotsu Hashimoto-Gotoh ◽  
Hideo Ohnishi ◽  
Atsushi Tsujimura ◽  
Hiroaki Tsunezuka ◽  
Kan Imai ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Bone Mass ◽  
Human Osteoblast ◽  
Mass Increase ◽  
Stimulating Factor ◽  
Bone Mass Increase

Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration

Bone ◽  
2018 ◽  
Vol 112 ◽  
pp. 24-34 ◽  
Author(s):  
Feng-Sheng Wang ◽  
Re-Wen Wu ◽  
Wei-Shiung Lain ◽  
Tsai-Chen Tsai ◽  
Yu-Shan Chen ◽  
...  
Keyword(s):  
Bone Mass ◽  
Mass Loss ◽  
Estrogen Deficiency ◽  
Bone Mass Loss

Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats

2021 ◽  
pp. 153537022110110
Author(s):  
Yu-Ting Cheng ◽  
Jian Liao ◽  
Qian Zhou ◽  
Hua Huo ◽  
Lucas Zellmer ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Mass Loss ◽  
Ovariectomized Rats ◽  
Therapeutic Effects ◽  
Bone Mass Loss ◽  
Cellular Effects ◽  
Protein Levels ◽  
Adverse Factor ◽  
Osteoclast Apoptosis

Bone mass loss (osteoporosis) seen in postmenopausal women is an adverse factor for implant denture. Using an ovariectomized rat model, we studied the mechanism of estrogen-deficiency-caused bone loss and the therapeutic effect of Zoledronic acid. We observed that ovariectomized-caused resorption of bone tissue in the mandible was evident at four weeks and had not fully recovered by 12 weeks post-ovariectomized compared with the sham-operated controls. Further evaluation with a TUNEL assay showed ovariectomized enhanced apoptosis of osteoblasts but inhibited apoptosis of osteoclasts in the mandible. Zoledronic acid given subcutaneously as a single low dose was shown to counteract both of these ovariectomized effects. Immunohistochemical staining showed that ovariectomized induced the protein levels of RANKL and the 65-kD subunit of the NF-κB complex mainly in osteoclasts, as confirmed by staining for TRAP, a marker for osteoclasts, whereas zoledronic acid inhibited these inductions. Western blotting showed that the levels of RANKL, p65, as well as the phosphorylated form of p65, and IκB-α were all higher in the ovariectomized group than in the sham and ovariectomized + zoledronic acid groups at both the 4th- and 12th-week time points in the mandible. These data collectively suggest that ovariectomized causes bone mass loss by enhancing apoptosis of osteoblasts and inhibiting apoptosis of osteoclasts. In osteoclasts, these cellular effects may be achieved by activating RANKL-NF-κB signalling. Moreover, zoledronic acid elicits its therapeutic effects in the mandible by counteracting these cellular and molecular consequences of ovariectomized.

scholarly journals Bromodomain Protein BRD4 Accelerates Glucocorticoid Dysregulation of Bone Mass and Marrow Adiposis by Modulating H3K9 and Foxp1

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1500
Author(s):  
Feng-Sheng Wang ◽  
Yu-Shan Chen ◽  
Jih-Yang Ko ◽  
Chung-Wen Kuo ◽  
Huei-Jing Ke ◽  
...  
Keyword(s):  
Bone Mass ◽  
Mass Loss ◽  
Osteogenic Differentiation ◽  
Progenitor Cells ◽  
Mesenchymal Progenitor Cells ◽  
Marrow Fat ◽  
Bone Mass Loss ◽  
Brd4 Inhibition ◽  
The Cost

Glucocorticoid provokes bone mass loss and fatty marrow, accelerating osteoporosis development. Bromodomain protein BRD4, an acetyl–histone-binding chromatin reader, regulates stem cell and tissue homeostasis. We uncovered that glucocorticoid inhibited acetyl Lys-9 at the histone 3 (H3K9ac)-binding Runx2 promoter and decreased osteogenic differentiation, whereas bromodomain protein 4 (BRD4) and adipocyte formation were upregulated in bone-marrow mesenchymal progenitor cells. BRD4 knockdown improved H3K9ac occupation at the Runx2 promoter and osteogenesis, but attenuated glucocorticoid-mediated adipocyte formation together with the unaffected H3K9ac-binding PPARγ2 promoter. BRD4 regulated epigenome related to fatty acid metabolism and the forkhead box P1 (Foxp1) pathway, which occupied the PPARγ2 promoter to modulate glucocorticoid-induced adipocytic activity. In vivo, BRD4 inhibitor JQ-1 treatment mitigated methylprednisolone-induced suppression of bone mass, trabecular microstructure, mineral acquisition, and osteogenic differentiation. Foxp1 signaling, marrow fat, and adipocyte formation in glucocorticoid-treated skeleton were reversed upon JQ-1 treatment. Taken together, glucocorticoid-induced H3K9 hypoacetylation augmented BRD4 action to Foxp1, which steered mesenchymal progenitor cells toward adipocytes at the cost of osteogenic differentiation in osteoporotic skeletons. BRD4 inhibition slowed bone mass loss and marrow adiposity. Collective investigations convey a new epigenetic insight into acetyl histone reader BRD4 control of osteogenesis and adipogenesis in skeleton, and highlight the remedial effects of the BRD4 inhibitor on glucocorticoid-induced osteoporosis.

Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women

2012 ◽  
Vol 52 (2) ◽  
pp. 717-726 ◽  
Author(s):  
Ángel A. López-González ◽  
Félix Grases ◽  
Nieves Monroy ◽  
Bartolome Marí ◽  
Mª Teófila Vicente-Herrero ◽  
...  
Keyword(s):  
Bone Mass ◽  
Protective Effect ◽  
Mass Loss ◽  
Postmenopausal Women ◽  
Inositol Hexaphosphate ◽  
Bone Mass Loss

Effectiveness and safety of medium- and long-term elcatonin use in the prevention and treatment of bone mass loss

1995 ◽  
Vol 56 (4) ◽  
pp. 385-399 ◽  
Author(s):  
Fernando Escobar Jiménez ◽  
Jose Miguel Aranburu Albizuri ◽  
Jose Maria Almirall Alier ◽  
Jorge Julian Molina Soto ◽  
Alfredo Gracia Canales
Keyword(s):  
Bone Mass ◽  
Mass Loss ◽  
Bone Mass Loss ◽  
Prevention And Treatment
Sign in / Sign up

Export Citation Format

Share Document